HIMS has experienced similar dramatic drops before. During the 2022 inflation surge, the stock fell 87%, and in 2020, it ...

Hims & Hers already offered dermatology services before buying Apostrophe and has continued to provide them after the acquisition. The company, which offers various services through its online ...

Shares of the health and wellness platform operator skyrocketed more than 670% between Jan. 1, 2024, and Feb. 19, 2025. However, this sizzling momentum came to a screeching halt in recent weeks. Hims ...

Hims & Hers Health (NYSE: HIMS) stock jumped 2.2% through 10:45 a.m. ET Monday after Morgan Stanley analyst ... now is the best time to buy before it’s too late. And the numbers speak for ...

Shares of Hims & Hers Health ... however, even after the significant decline in the stock price following the loss of its ability to compound semaglutide. Before making an investment in the ...

Hims & Hers has risen 70% since November ... well above analysts' estimates before the earnings release of $489.91 million. After earnings, analysts raised their revenue estimates to $534.97.

CFO Oluyemi Okupe confirmed on Hims & Hers Health's fourth-quarter earnings call a few days after the FDA announcement ... based on its business prospects before the FDA decision led to a sharp ...

CFO Oluyemi Okupe confirmed on Hims & Hers Health's fourth-quarter earnings call a few days after the FDA announcement that semaglutide "will not be offered on the platform after the first quarter." ...